Quotes Newron Pharmaceuticals S.p.A. Deutsche Boerse AG
Stocks
NP5
IT0004147952
Biotechnology & Medical Research
|
Market Closed -
Deutsche Boerse AG
02:05:42 2026-08-28 EDT
|
5-day change | 1st Jan Change | ||
| 13.30 EUR | +3.50% |
|
-0.37% | -50.09% |
| 07-03 | Newron Pharmaceuticals to Make Changes to Phase 3 Trial of Schizophrenia Treatment | MT |
| 05-05 | Edison Is Not Overly Concerned About a Trial Suspension |  |
Stock exchange
Deutsche Boerse AG
NP5 13.30 €
+3.50%
0
€
| Markets | Price | Change | Volumes | ||
|---|---|---|---|---|---|
| NWRN | 12.36CHF | -1.90% | 379K CHF | ||
CBOE
| 0QOI | 12.30CHF | -1.76% | 45.74K CHF | |
|
Tradegate
| NP5 | 13.15EUR | -2.59% | 15.45K € | |
|
Xetra
| NP5 | 13.20EUR | -1.86% | 10.05K € | |
|
Boerse Muenchen
| NP5 | 13.20EUR | -1.86% | 9.75K € | |
|
Deutsche Boerse AG
| NP5 | 13.30EUR | +3.50% | 0 € | |
|
Börse Stuttgart
| NP5 | 13.10EUR | -2.60% | 0 € |
Quotes 5-day view: Newron Pharmaceuticals S.p.A.
Delayed Quote Deutsche Boerse AG
| 2026-08-24 | 2026-08-25 | 2026-08-26 | 2026-08-27 | 2026-08-28 | |
|---|---|---|---|---|---|
| Last | €13.25 | €12.90 | €13.00 | €12.85 | €13.30 |
| Volume | 500 | 0 | 0 | 0 | 0 |
| Change | -0.75% | -2.64% | +0.78% | -1.15% | +3.50% |
| Opening | €13.25 | €12.90 | €13.00 | €12.85 | €13.30 |
| High | €13.25 | €12.90 | €13.00 | €12.85 | €13.30 |
| Low | €13.25 | €12.90 | €13.00 | €12.85 | €13.30 |
Performance
| 1 day | +3.50% | ||
| 1 week | -0.37% | ||
| Current month | +5.56% | ||
| 1 month | +9.92% | ||
| 3 months | -13.07% | ||
| 6 months | -30.29% | ||
| Current year | -50.09% | ||
| 1 year | +49.94% | ||
| 3 years | +137.50% | ||
| 5 years | +600.00% | ||
| 10 years | +4.77% |
Volumes
marketsDaily volume
0
Estimated daily volume
0
Avg. Volume 20 sessions
114
Daily volume ratio
0
Avg. Volume 20 sessions
1,516.2
Avg. Volume 20 sessions USD
1,757.49
Record volume 1
31,741
Record volume 2
27,594
Record volume 3
23,216
Capital turnover ratio
0
Float rotation
0
Basic data
Market Cap (EUR)
274,274,344
Market Cap (USD)
318,294,469
Net sales (EUR)
19,126,000
Net sales (USD)
22,195,660
Number of employees
27
Sales / Employee (EUR)
708,370
Sales / Employee (USD)
822,061
Free-Float
86.89 %
Free-Float capitalization (EUR)
238,328,631
Free-Float capitalization (USD)
276,579,588
Average Daily Capital Traded
0%
Indicators
Moving average 5 days
13.06
Moving average 20 days
13.04
Moving average 50 days
12.95
Moving average 100 days
14.09
Price spread / (MMA5)
-1.80%
Price spread / (MMA20)
-1.97%
Price spread / (MMA50)
-2.64%
Price spread / (MMA100)
+5.92%
STIM
RSI 9 days
45.06
RSI 14 days
47.55
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.50% | -0.37% | +49.94% | +137.50% | 318M | |
| -0.78% | -1.42% | +2.96% | +20.82% | 50.47B | |
| -6.00% | -0.75% | +447.48% | +524.26% | 44.56B | |
| -0.24% | +0.74% | +37.18% | +16.57% | 43.08B | |
| -1.55% | -2.07% | +19.83% | +73.63% | 41.7B | |
| -0.31% | -0.83% | +19.47% | +48.24% | 33.21B | |
| -1.79% | -3.24% | +26.32% | +121.63% | 16.77B | |
| -0.58% | -2.12% | - | - | 16.28B | |
| -0.88% | -0.66% | +11.63% | +28.71% | 14.58B | |
| -1.66% | -1.25% | +78.49% | +39.02% | 13.92B | |
| Average | -1.03% | -1.39% | +77.03% | +112.26% | 27.49B | |
| Weighted average by Cap. | -1.70% | -1.21% | +96.22% | +127.00% |
Historical Quotes: Newron Pharmaceuticals S.p.A.
| Date | Opening | High | Low | Close | Volume | Change |
|---|
Price Extremes
| 1 week | 12.85 |  | 13.3 |
| 1 month | 12.4 | | 14.1 |
| Current year | 12.05 | | 33.55 |
| 1 year | 8.55 | | 33.55 |
| 3 years | 4.2 | | 33.55 |
| 5 years | 1 | | 33.55 |
| 10 years | 1 | | 33.55 |
Monthly variations
Annual variations
| 2026 | -50.09% | ||
| 2025 | +186.87% | ||
| 2024 | +65.89% | ||
| 2023 | +280.95% | ||
| 2022 | -2.13% | ||
| 2021 | -21.44% | ||
| 2020 | -66.46% | ||
| 2019 | -55.10% | ||
| 2010 | +1.64% | ||
| 2009 | +35.61% | ||
| 2008 | -66.64% | ||
| 2007 | -16.74% | ||
| 2006 | +2.03% |
- Stock Market
- Stocks
- NWRN Stock
- NP5 Stock
- Quotes Newron Pharmaceuticals S.p.A.
Select your edition
All financial news and data tailored to specific country editions
